Cite

HARVARD Citation

    Khan, N. et al. (n.d.). A PHASE II TRIAL OF REDUCED DOSE BRENTUXIMAB VEDOTIN FOR CUTANEOUS T‐CELL LYMPHOMAS. Hematological oncology. p. n/a. [Online]. 
  
Back to record